Traditional Chinese medicine combined with individualized chemotherapy in patients with advanced non-small cell lung cancer: A prospective randomized controlled trial
10.3781/j.issn.1000-7431.2015.33.400
- Author:
Shengping SHEN
1
Author Information
1. Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital of Shanghai Jiao Tong University
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Carcinoma;
Chinese materia medica;
Individualized treatment;
Non-small cell lung;
Quality of life;
Survival anslysis;
Traditional Chinese medicine;
Treatment outcomes
- From:
Tumor
2015;35(10):1120-1126
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and adverse effects ofindividualized chemotherapy combined with traditional Chinese medicine (TCM) in treatment for advanced non-small cell lung cancer (NSCLC) and its prognosis. Methods: A prospective randomized controlled trial was designed to recruit 100 eligible patients with refractory stage IIIB-IV NSCLC from Shanghai Chest Hospital of Shanghai Jiao Tong University between January 1, 2013 and May 31, 2014. The 100 patients were randomized divided into study group (N = 50) and control group (N = 50). The patients in the study group received individualized chemotherapy according to the results of detection of molecular targets combined with traditional Chinese medicine by syndrome differentiation, while the patients in the control group received chemotherapy with vinorelbine and gemcitabine. The response after treatment and the quality of life score and TCM symptom score before treatment and three months after four cycles of chemotherapy (or last chemotherapy) between two groups were compared. The progression-free survival (PFS) was calculated by Kaplan-Meier method. The treatment-related adverse reactions were observed. Results: In study group, 7 patients achieved partial response (PR), 30 patients achieved stable disease (SD), and 13 patients achieved progressive disease (PD); in the control group, 3 achieved PR, 22 achieved SD, and 25 achieved PD. The response of study group was significantly better than that of the control group (P = 0.037). The median PFS in study group and the control group were 3.8 and 3.3 months, respectively; there was a significant difference between the two groups (P = 0.043). Before treatment, there were no significant differences in quality of life and TCM symptom scores between two groups (both P > 0.05). After treatment, the quality of life and TCM symptom scores of the study group were significantly improved as compared with those of the control group (both P < 0.05). The rates of fatigue and constipation in the study group were significantly higher than those in the control group (both P < 0.05). Conclusion: The treatment with individualized chemotherapy combined with TCM may benefit the response, clinical symptoms, quality of life and PFS of patients with advanced NSCLC.
